STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Status:
Withdrawn
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
In this research study, the investigators are looking to determine the safety and efficacy of
an investigational drug, STA9090 alone and in combination with dutasteride for the treatment
of castrate resistant prostate cancer. STA9090 may cause the growth of cancer to slow down or
shrink by targeting proteins required for the cancer to grow. The investigators are also
looking to determine whether the use of dutasteride to lower male hormone levels will enhance
the effect of STA9090 in the treatment of castrate resistant prostate cancer.